Table 1

Baseline and Procedural Characteristics of Patients in the Randomized PLATINUM Trial and the SV and LL Substudies

Randomized CoCr-EES (n = 762)Randomized PtCr-EES (n = 768)SV Study (n = 94)LL Study (n = 102)
Patient characteristics
 Age, yrs63.1 ± 10.364.0 ± 10.364.33 ± 11.0365.94 ± 9.79
 Male542 (71.1)550 (71.6)68 (72.3)64 (62.7)
 Caucasian644 (84.5)650 (84.6)80 (85.1)83 (81.4)
 Hypertension558 (73.2)544/767 (70.9)75 (79.8)84 (82.4)
 Hyperlipidemia579/760 (76.2)598/765 (78.2)77 (81.9)84 (82.4)
 Diabetes191 (25.1)169 (22.0)40 (42.6)30/100 (30.0)
 Smoking, ever448/741 (60.5)493/751 (65.6)59 (62.8)64/100 (64.0)
 Prior myocardial infarction160/760 (21.1)160/761 (21.0)28 (29.8)34 (33.3)
 Unstable angina188 (24.7)185/767 (24.1)23 (24.5)24/101 (23.8)
Number of target lesions
 1684 (89.8)683 (88.9)94 (100)102 (100)
 277 (10.1)85 (11.1)00
Target lesion characteristics
 Reference vessel diameter, mm2.63 ± 0.492.67 ± 0.492.04 ± 0.262.56 ± 0.40
 Minimum lumen diameter, mm0.74 ± 0.340.75 ± 0.350.51 ± 0.210.73 ± 0.30
 Diameter stenosis, mm71.9 ± 11.571.8 ± 11.575.1 ± 9.571.7 ± 10.96
 Lesion length, mm12.5 ± 5.513.0 ± 5.714.15 ± 7.0324.38 ± 8.21
Target vessel
 Left anterior descending343/813 (42.2)347/824 (42.1)32 (34.0)44 (43.1)
 Left circumflex216/813 (26.6)217/824 (26.3)41 (43.6)22 (21.6)
 Right254/813 (31.2)260/824 (31.6)21 (22.3)36 (35.3)
Procedure characteristics
 No. of stents per patient1.20 ± 0.481.16 ± 0.441.00 ± 0.291.13 ± 0.36
 Total stent length per lesion, mm19.7 ± 8.920.5 ± 7.020.13 ± 7.3837.51 ± 8.49
 Maximum dilation pressure, atm15.9 ± 3.216.3 ± 3.116.03 ± 3.3917.50 ± 3.03

Values are mean ± SD, n (%), or n/N (%).

CoCr-EES = cobalt chromium everolimus-eluting stent(s); LL = long lesion; PLATINUM = PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions; PtCr-EES = platinum-chromium everolimus-eluting stent(s); SV = small vessel.

  • Requiring medication.